A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination with Pembrolizumab in Patients with Metastatic or Unresectable, Locally Advanced Colorectal Cancer
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Isunakinra (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Buzzard Pharmaceuticals
- 15 Oct 2024 New trial record